GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer | Version 2.0
What does an LDL-C of 80 mg/dL tell you?
Two patients return with the same LDL-C. One started at 200 mg/dL, the other at 100 mg/dL. The updated analyzer puts the untreated value back in view and shows how much LDL-C changed. It also checks whether the patient is eligible for an absolute cardiovascular risk estimate.
Start with the untreated LDL-C
A follow-up lipid panel answers two questions. How much has LDL-C fallen since treatment began? Is the current concentration appropriate for this patient’s cardiovascular risk? The 2026 ACC/AHA dyslipidemia guideline uses both the percentage reduction from baseline and the absolute lipid goal to assess response.[1]
| Untreated LDL-C | Current LDL-C | Reduction |
|---|---|---|
| 200 mg/dL | 80 mg/dL | 60% |
| 100 mg/dL | 80 mg/dL | 20% |
For the first patient, the untreated LDL-C of 200 mg/dL still warrants review for severe hypercholesterolemia, even after a 60% reduction. In the second case, the 20% reduction becomes meaningful once the clinician knows the treatment prescribed, how consistently the patient took it, and the goal for that patient’s risk category. An LDL-C of 80 mg/dL alone settles neither question.[1]
In v2.0, enter the current LDL-C and, if available, a documented value obtained before lipid-lowering therapy. The report displays both values and their percentage change. When the untreated value is unknown, leave it blank and proceed with the current panel. Go to the lipid entry fields.
When should a PREVENT percentage appear?
The AHA PREVENT equations estimate the risk of a first cardiovascular event. In eligible adults aged 30 to 79, the analyzer reports separate 10-year estimates for atherosclerotic cardiovascular disease (ASCVD), heart failure, and total cardiovascular disease. For ages 30 to 59, it also reports 30-year estimates. This can help frame a prevention discussion with a younger adult whose short-term event risk is low.[2][3]
Consider a patient with an estimated glomerular filtration rate (eGFR) of 10 mL/min/1.73 m2. The AHA calculator’s input range begins at 15. Version 2.0 identifies the out-of-range value and withholds the percentage. The clinician can still review the lipid panel and kidney findings. A history of myocardial infarction or established heart failure also changes the assessment because the model was developed for primary prevention.[2]
The app uses the PREVENT base equations. Hemoglobin A1c and urine albumin-to-creatinine ratio appear separately in the clinical interpretation when entered. Review the analyzer’s methods and eligibility limits.
What ApoB and triglycerides add to the follow-up visit
When LDL-C has fallen but triglycerides remain elevated, a clinician may still want to know how many atherogenic particles are circulating. Non-HDL-C captures the cholesterol carried by these particles. Apolipoprotein B (ApoB) provides an estimate of their number. Version 2.0 flags ApoB of 120 mg/dL or higher as a risk enhancer under the 2026 guideline. The applicable treatment goal depends on the patient’s risk category.[1]
Fasting status can change the interpretation of the same triglyceride result. A value of 160 mg/dL crosses the fasting risk-enhancer threshold of 150 mg/dL and falls below the nonfasting threshold of 175 mg/dL. The guideline specifies persistent elevation, so the collection conditions and earlier results matter before recording a risk enhancer.[1]
Lipoprotein(a), or Lp(a), adds information about inherited risk. Enter it in the unit on the laboratory report. For a fuller discussion of why these measurements can point in different directions, see the original article’s sections on ApoB and LDL-C discordance and lipoprotein(a).
Using the report during a chart review
Start with the values already in the chart. Version 2.0 brings priority findings and available risk estimates to the top of the report. The missing-data section identifies which inputs would complete the assessment. If LDL-C exceeds non-HDL-C, for example, the app asks the user to verify the results, units and collection date before interpreting the panel.
For the two patients whose LDL-C is now 80 mg/dL, the most useful chart entry includes the untreated value, the percentage change, and the prevention context. With those details together, the next clinician can see why the same follow-up result led to a different discussion.
Clinical references
- Blumenthal RS, Morris PB, et al. 2026 ACC/AHA multisociety guideline on the management of dyslipidemia. See Table 13 for risk enhancers and section 4.2.4.3 for severe hypercholesterolemia. Read the guideline.
- American Heart Association. PREVENT Equations Quickstart Guide. See patient eligibility and the required input ranges in the calculator instructions. Read the AHA guide.
- American Heart Association. Using PREVENT-ASCVD Equations for Risk-Based Lipid Management. See take-home messages 2 and 7 for age ranges and use of the 30-year estimate. Read the clinical summary.